Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Milestone or anyone, can PTSC afford to hold on to their interest in the MMP for

Alliacense controls the licensing on behalf of PTSC/Moore/TPL of the still valid MMP Portfolio patents.

With your $7 million figure, you discount the 2 recent licenses, settlement of the ARS arbitration, and any further licencees. I don't believe that your scenario will occur because of these facts and also the USPTO has time deadlines for responses to any Office Actions which means that it can't be dragged out indefinitely. Costs to PTSC are also costs to TPL.



How might shareholders, by using the internet, gain control of PTSC?



One point not touched upon from the CC is the reliance on historical models. If the Company were to persist in using them, as they are, I would humbly suggest that they leave themselves open to litigation, unless they expect further revenues from the MMP Portfolio.





Be well

Share
New Message
Please login to post a reply